Oxford Cannabinoid Technologies – executive interview

Oxford Cannabinoid Technologies – executive interview

Oxford Cannabinoid Technologies — 1 video in collection

More on this equity

Based in the UK, Oxford Cannabinoid Technologies is focused on advancing cannabinoid medicines for the treatment of pain and other indications. Lead asset OCT461201 is a CB2 selective agonist being investigated for the treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy and visceral pain in irritable bowel syndrome as initial pain indications. These therapies would be an alternative to opioid therapies, which have been limited in distribution in light of the opioid abuse epidemic. New drugs that target the endocannabinoid system may represent an innovative solution to address this need.

In this interview, CEO Clarissa Sowemimo-Coker provides a recap of the company’s efforts and pipeline.


You may also be interested in these:

Healthcare

Oryzon Genomics – executive interview

Healthcare

Basilea Pharmaceutica – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free